Metastatic alveolar RMS (ARMS) presents a major clinical challenge, particularly due to chemotherapy resistance driven by the PAX3-FOXO1 fusion protein, which alters cell-cycle checkpoint control [255]. Here, FOXO1 is linked to alveolar rhabdomyosarcoma.